National Registry Study on Treatment and Outcomes in Advanced Renal Cell and Urothelial Cancers in Germany

What this Trial Is About

Researchers are conducting a national, prospective, longitudinal, multicenter observational study called CARAT to collect detailed information on patients with advanced renal cell carcinoma and urothelial cancer in Germany. This study aims to gather uniform data on patient characteristics, molecular diagnostics, treatments, and disease progression. It includes patients with advanced renal carcinoma, advanced urothelial cancer, and muscle-invasive bladder cancer, tracking their treatment courses and outcomes over several years. Participants receive routine care as per their treating physicians choice, reflecting standard clinical practice. The study follows patients with advanced renal carcinoma for up to three years, those with advanced urothelial cancer for up to two years, and patients with muscle-invasive bladder cancer for up to five years. Data collection includes systemic treatments, surgeries, radiotherapies, perioperative therapies, and neoadjuvant therapies, depending on the cancer type and patient cohort. During the study, researchers collect data on patient characteristics, tumor features, previous and ongoing treatments, and outcomes, including patient-reported health-related quality of life for up to two years. They monitor treatment responses, progression-free survival, overall survival, and symptom-related quality of life. This comprehensive data helps identify common treatment sequences and changes over time, providing valuable insights into the real-world management of these cancers.

Registry Platform Urologic Cancer